The United Kingdom and the United States have signed a major bilateral deal that will guarantee zero levies on British drug products going into the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to boost expenditure on drugs through the National Health Service (NHS). This pledge secures that import taxes on these crucial exports will be held at zero for a period of three years.
This deal is in response to previous statements to hike import taxes on patented pharmaceutical products, with figures mentioned as high as double the cost.
"This deal between the UK bolsters the worldwide climate for innovative medicines and establishes long-overdue balance to American-British pharmaceutical trade," a statement said.
Trade Impact
Medicines represent one of the Britain's largest goods shipped to the America, which is by far the largest buyer for leading UK drugmakers.
Statistics reveal that in the 12 months leading up to the third quarter, the UK exported drugs worth £11.1bn to the US. This amount accounted for a significant portion of all goods exports in that period.
"This agreement safeguards jobs, boosts funding and paves the way for the UK to become a worldwide center for life sciences," a minister commented.
Key British Pledges
The pact involves several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it judges new therapies to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a goal to raise total NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The amount drug companies must return to the NHS to stay within budget will be capped at fifteen percent. Last year, repayments were more than 20%.
Industry Background
The deal follows a long-running tension between the sector and the UK government over spending levels and approval rates.
The disagreement were heightened by claims that American consumers were charged a premium for the same drugs than patients in the Britain and the EU.
Recently, several large pharmaceutical investments in the UK have been halted or scrapped, while substantial expansions have been announced toward American operations.
One official publicly accepted that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the last ten years.
